AI주식인사이트AI Stock Insight
B

삼성에피스홀딩스

0126Z0KOSPI기타 금융업

58.5 / 100

Reference Date: 2026-04-13

Financial Score19.0 / 40
News Sentiment18.5 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but PBR raises overvaluation concerns. Slightly up 2.8% over the past month, and news sentiment is positive.

Company InformationBased on 2025 Annual Report

Business Overview

Samsung Epis Holdings is a biotech investment holding company with two subsidiaries, Samsung Bioepis and Epis Nex Lab. Samsung Bioepis focuses on commercializing 11 biosimilar products, contributing 96.7% of 2025 revenue, and is expanding into ADC drug development. Epis Nex Lab, established in 2025, is focused on next-generation biotech platforms but has not yet generated revenue.

Number of Employees

18people

Average Salary

—

Score Calculation Basis

Detailed Financial Score

PER
—Industry Average 10.014.0Point
PBR
2.35Industry Average 0.480.0Point

4.9x industry avg (risky)

ROE
—Industry Average 5.513.5Point
Debt Ratio
9.07Industry Average 19.366.5Point

Half of industry avg (excellent)

Trend 5.0 / 10 points
Revenue Growth Rate
1.5 / 3

Operating Profit Growth Rate
1.5 / 3

ROE Trend
2.0 / 4

Detailed News Sentiment

13 totalPositive 9Neutral 2Negative 0Average Sentiment Score 78.2

Detailed Momentum

52-week position5.0Point

52w mid range (51%)

Current 547,000Won52-week high 743,00052-week low 335,500
1-month return4.0Point

1m +2.82% (slight rise)

Volume trend2.0Point

Volume decreasing

Detailed Disclosure

8 totalPositive 0Neutral 8Negative 0
  • Neutral결산실적공시예고(안내공시)2026-04-09
  • Neutral주식등의대량보유상황보고서(약식)2026-04-01
  • Neutral최대주주등소유주식변동신고서2026-03-23
  • Neutral사외이사의선임ㆍ해임또는중도퇴임에관한신고2026-03-20
  • Neutral정기주주총회결과2026-03-20